Wave Life Sciences Ltd.
WVEDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 2 past
How WVE's past catalysts played out
WVE-006
Alpha-1 Antitrypsin Deficiency
WVE-N531
Duchenne Muscular Dystrophy
SAD: 30mg WVE-003
Huntington Disease
WVE-007
Overweight and Obesity
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
WVE-006 | Phase 2 | Alpha-1 Antitrypsin Deficiency | - | - |
WVE-N531 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
SAD: 30mg WVE-003 | Phase 2 | Huntington Disease | - | - |
WVE-007 | Phase 2 | Overweight and Obesity | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Wave Life Sciences Ltd.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Wave Life Sciences Ltd.'s (WVE) pipeline across Phase 2. Its lead program is WVE-006 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Wave Life Sciences Ltd.'s next FDA catalyst?→
Wave Life Sciences Ltd.'s (WVE) next tracked catalyst is a Earnings expected July 29, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track WVE biotech catalysts?→
Add WVE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Wave Life Sciences Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.